These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38443742)

  • 1. Cost-effectiveness of sodium zirconium cyclosilicate for advanced chronic kidney patients in Singapore.
    Chay J; Choo JCJ; Finkelstein EA
    Nephrology (Carlton); 2024 May; 29(5):278-287. PubMed ID: 38443742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of sodium zirconium cyclosilicate for hyperkalemia among patients with chronic kidney disease or heart failure in Kuwait.
    Elsisi GH; Mahmoud MMI; Al-Humood K; Al-Yousef A
    J Med Econ; 2024; 27(1):253-265. PubMed ID: 38318718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of sodium zirconium cyclosilicate for the treatment of hyperkalaemia in patients with CKD in Norway and Sweden.
    Kim K; Fagerström J; Chen G; Lagunova Z; Furuland H; McEwan P
    BMC Nephrol; 2022 Aug; 23(1):281. PubMed ID: 35953778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of sodium zirconium cyclosilicate for treating hyperkalemia among Chinese patients.
    Tian L; Fu S; Li M; Zhao X; Li H
    Front Public Health; 2023; 11():1196789. PubMed ID: 38145082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure.
    Ward T; Lewis RD; Brown T; Baxter G; de Arellano AR
    BMC Nephrol; 2023 Mar; 24(1):47. PubMed ID: 36890464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Modifications of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Hyperkalemia Initiating Sodium Zirconium Cyclosilicate Therapy: The OPTIMIZE I Study.
    Agiro A; An A; Cook EE; Mu F; Chen J; Desai P; Oluwatosin Y; Pollack CV
    Adv Ther; 2023 Jun; 40(6):2886-2901. PubMed ID: 37140706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potassium binders for chronic hyperkalaemia in people with chronic kidney disease.
    Natale P; Palmer SC; Ruospo M; Saglimbene VM; Strippoli GF
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD013165. PubMed ID: 32588430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The LIFT trial: study protocol for a double-blind, randomised, placebo-controlled trial of K
    Murphy D; Ster IC; Kaski JC; Anderson L; Banerjee D
    BMC Nephrol; 2021 Jul; 22(1):254. PubMed ID: 34229607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia.
    Takkar C; Nassar T; Qunibi W
    Expert Opin Pharmacother; 2021 Jan; 22(1):19-28. PubMed ID: 32892634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium zirconium cyclosilicate for the management of chronic hyperkalemia in kidney disease, a novel agent.
    Rastogi A; Hanna RM; Mkrttchyan A; Khalid M; Yaqoob S; Shaffer K; Dhawan P; Nobakht N; Kamgar M; Goshtaseb R; Sarmosyan K; Gnarini M; Wassef O; Lerma E
    Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1055-1064. PubMed ID: 34227913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness Analysis of Patiromer in Combination with Renin-Angiotensin-Aldosterone System Inhibitors for Chronic Kidney Disease in Sweden.
    Widén J; Ivarsson M; Schalin L; Vrouchou P; Schwenkglenks M; Heimbürger O; Ademi Z; Sutherland CS
    Pharmacoeconomics; 2020 Jul; 38(7):747-764. PubMed ID: 32239480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Sodium Zirconium Cyclosilicate Plus Renin-Angiotensin-Aldosterone System Inhibitor Therapy on Short-Term Medical Costs in Hyperkalemia: OPTIMIZE II Real-World Study.
    Dwyer JP; Agiro A; Desai P; Oluwatosin Y
    Adv Ther; 2023 Nov; 40(11):4777-4791. PubMed ID: 37606716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects and Safety of a Novel Oral Potassium-Lowering Drug-Sodium Zirconium Cyclosilicate for the Treatment of Hyperkalemia: a Systematic Review and Meta-Analysis.
    Zhang Y; Xu R; Wang F; Liu Y; Xu J; Zhao N; Cheng F; Long L; Jia J; Lin S
    Cardiovasc Drugs Ther; 2021 Oct; 35(5):1057-1066. PubMed ID: 33459923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, Phase 3 study.
    Roger SD; Lavin PT; Lerma EV; McCullough PA; Butler J; Spinowitz BS; von Haehling S; Kosiborod M; Zhao J; Fishbane S; Packham DK
    Nephrol Dial Transplant; 2021 Jan; 36(1):137-150. PubMed ID: 32030422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium zirconium cyclosilicate increases serum bicarbonate concentrations among patients with hyperkalaemia: exploratory analyses from three randomized, multi-dose, placebo-controlled trials.
    Roger SD; Spinowitz BS; Lerma EV; Fishbane S; Ash SR; Martins JG; Quinn CM; Packham DK
    Nephrol Dial Transplant; 2021 Apr; 36(5):871-883. PubMed ID: 32588050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium zirconium cyclosilicate reconciles management of hyperkalemia and continuity of renin-angiotensin-aldosterone system inhibitors: a retrospective observational study.
    Kimura W; Minatoguchi S; Mizuno T; Koide S; Hayashi H; Hasegawa M; Inaguma D; Tsuboi N
    J Nephrol; 2024 Jan; 37(1):171-179. PubMed ID: 37608241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperkalaemia and potassium binders: Retrospective observational analysis looking at the efficacy and cost effectiveness of calcium polystyrene sulfonate and sodium zirconium cyclosilicate.
    Huda AB; Langford C; Lake J; Langford N
    J Clin Pharm Ther; 2022 Dec; 47(12):2170-2175. PubMed ID: 36114759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mortality and hyperkalaemia-associated hospitalisation in patients with chronic kidney disease: comparison of sodium zirconium cyclosilicate and sodium/calcium polystyrene sulfonate.
    Onogi C; Watanabe Y; Tanaka A; Furuhashi K; Maruyama S
    Clin Kidney J; 2024 Feb; 17(2):sfae021. PubMed ID: 38404365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintained renin-angiotensin-aldosterone system inhibitor therapy with sodium zirconium cyclosilicate following a hyperkalaemia episode: a multicountry cohort study.
    Rastogi A; Pollack CV; Sánchez Lázaro IJ; Lesén E; Arnold M; Franzén S; Allum A; Hernández I; Murohara T; Kanda E
    Clin Kidney J; 2024 May; 17(5):sfae083. PubMed ID: 38699484
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.